TITLE

Pharmacokinetics and Pharmacodynamics of Nelfinavir Administered Twice or Thrice Daily to Human Immunodeficiency Virus Type 1--Infected Children

AUTHOR(S)
Gatti, G.; Castelli-Gattinara, G.; Cruciani, M.; Bernardi, S.; De Pascalis, C.R.; Pontali, E.; Papa, L.; Miletich, F.; Bassetti, D.
PUB. DATE
June 2003
SOURCE
Clinical Infectious Diseases;6/1/2003, Vol. 36 Issue 11, p1476
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
We studied the pharmacokinetics and pharmacodynamics of nelfinavir administered 2 or 3 times per day to human immunodeficiency virus type 1 (HIV-1)-infected children receiving highly active antiretroviral therapy containing nelfinavir. The geometric mean trough concentrations of nelfinavir for the thrice- and twice-daily regimens were 1.55 mg/L and 1.11 mg/L, respectively (P = not significant). Nelfinavir concentrations did not correlate with total daily dose, dose per kilogram of weight, age, weight, previous protease inhibitor (PI) experience, or CD4[sup +] cell percentage. In the 25 PI-naive children, the virus load reductions at 24 weeks of treatment with the twice- and thrice-daily regimens were comparable. A significantly higher percentage of children in the twice-daily group had a trough concentration of nelfinavir of less than the inhibitory concentration of 95% (P = .042). The decrease in the virus load at 24 weeks of treatment was not correlated with the trough concentration of nelfinavir. The variability of trough concentrations was extremely high, particularly among recipients of the twice-daily regimen, resulting in a higher number of patients with subinhibitory concentrations of nelfinavir in this group.
ACCESSION #
10029859

 

Related Articles

  • Stavudine: An Update of its Use in the Treatment of HIV Infection. Hurst, M.; Noble, S. // Drugs;Nov1999, Vol. 58 Issue 5, p919 

    Stavudine is a thymidine nucleoside analogue which is phosphorylated intracellularly to an active metabolite, stavudine 5′-triphosphate. This metabolite inhibits HIV replication, either by competing with thymidine 5′-triphosphate for incorporation into viral DNA by reverse...

  • Antiretroviral drug treatment of CNS HIV-1 infection. Yilmaz, Aylin; Price, Richard W.; Gisslén, Magnus // Journal of Antimicrobial Chemotherapy (JAC);Feb2012, Vol. 67 Issue 2, p299 

    The advent of combination antiretroviral treatment has had a profound impact on CNS HIV infection and its clinical complications, but neurological impairment still occurs in patients on systemically effective combination therapy, and in some patients it may be important to consider...

  • Pharmacokinetic Optimization of Antiretroviral Therapy in Children and Adolescents.  // Clinical Pharmacokinetics;2011, Vol. 50 Issue 3, p143 

    No abstract available.

  • Pharmacokinetics and Pharmacodynamics of Darunavir and Etravirine in HIV-1-Infected, Treatment-Experienced Patients in the Gender, Race, and Clinical Experience (GRACE) Trial. Kakuda, Thomas; Sekar, Vanitha; Vis, Peter; Coate, Bruce; Ryan, Robert; Anderson, David; De La Rosa, Guy; Mrus, Joseph // AIDS Research & Treatment;2012, p1 

    Objectives. Evaluation of pharmacokinetics and pharmacodynamics of darunavir and etravirine among HIV-1-infected, treatment experienced adults from GRACE, by sex and race. Methods. Patients received darunavir/ritonavir 600/100 mg twice daily plus other antiretrovirals, which could include...

  • Tenofovir Disoproxil Fumarate in the Clinical Practice: An Overview. Foggia, Maria; Nappa, Salvatore; Bonadies, Giovanni; Cotugno, Mariarosaria; Di Filippo, Giovanni; Borrelli, Francesco; Orlando, Raffaele; Borgia, Guglielmo // Anti-Infective Agents in Medicinal Chemistry;2008, Vol. 7 Issue 4, p285 

    Tenofovir disoproxil fumarate (tenofovir DF) is the generic name of the chemical compound 9- [R- (2[[bis]]isopropoxycarbonyl) oxy]methoxy]phosphonyl]methoxy]propyl] adenine fumarate (1:1), the prodrug of tenofovir, the first nucleotide analogue reverse transcriptase inhibitor approved in October...

  • Influence of Protease Inhibitors on the Pharmacodynamics of Gliclazide in Rats. Shaik, Mastan; Kilari, Eswar Kumar // International Online Medical Conference (IOMC) Conference Procee;2010, Vol. 1 Issue 1, p284 

    Background: Type 2 diabetes may occur as a result of HIV-infection and/or its treatment with protease inhibitors. Indinavir, ritonavir and atazanavir are widely used protease inhibitors for the treatment of HIV-infection. Gliclazide is a widely used drug for the treatment of type 2 diabetes. So...

  • The relation between treatment outcome and efavirenz, atazanavir or lopinavir exposure in the NORTHIV trial of treatment-naïve HIV-1 infected patients. Josephson, Filip; Andersson, Maria; Flamholc, Leo; Gisslén, Magnus; Hagberg, Lars; Ormaasen, Vidar; Sönnerborg, Anders; Vesterbacka, Jan; Böttiger, Ylva // European Journal of Clinical Pharmacology;Apr2010, Vol. 66 Issue 4, p349 

    The relation between treatment outcome and trough plasma concentrations of efavirenz (EFV), atazanavir (ATV) and lopinavir (LPV) was studied in a pharmacokinetic/pharmacodynamic substudy of the NORTHIV trial—a randomised phase IV efficacy trial comparing antiretroviral-naïve human...

  • tenofovir disoproxil fumarate.  // Davis's Drug Guide for Nurses, 10th edition;2007, p1111 

    The article presents a nursing guide for antiretroviral agent tenofovir disoproxil fumarate. It is used to manage HIV infections. The physiological effects, pharmacokinetics, contraindications, and side effects of tenofovir disoproxil fumarate are outlined. The drug's interactions with other...

  • Effect of Adherence as Measured by MEMS, Ritonavir Boosting, and CYP3A5 Genotype on Atazanavir Pharmacokinetics in Treatment-Naive HIV-Infected Patients. Savic, R M; Barrail-Tran, A; Duval, X; Nembot, G; Panhard, X; Descamps, D; Verstuyft, C; Vrijens, B; Taburet, A-M; Goujard, C; Mentré, F // Clinical Pharmacology & Therapeutics;Nov2012, Vol. 92 Issue 5, p575 

    We investigated population pharmacokinetics and pharmacogenetics of ritonavir-boosted atazanavir (ATV), using drug intake times exactly recorded by the Medication Event Monitoring System. The ANRS 134-COPHAR 3 trial was conducted in 35 HIV-infected treatment-naive patients. ATV (300 mg),...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics